INEDES   24797
INSTITUTO DE ECOLOGIA Y DESARROLLO SUSTENTABLE
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
TRASTUZUMAB-CONJUGATED HOLLOW POROUS SILICA NANOPARTICLES FOR HER2+ TARGETED THERAPY IN BREAST CANCER
Autor/es:
RODRÍGUEZ CRISTINA; FISZMAN, GABRIEL; MITAROTONDA, ROMINA; DE MARZI, MAURICIO; TAPIA, IVANA; DESIMONE, MARTÍN
Lugar:
Mar del Plata
Reunión:
Congreso; LXIII Reunión Científica Anual de la Sociedad Argentina de Investigación Clínica. LXVI Reunión Científica Anual de la Sociedad Argentina de Inmunología.; 2018
Institución organizadora:
SAI-SAC-SAFE-SAFI
Resumen:
Conjugation of nanoparticles (NPs) with ligands of cancer specific tumor biomarkers is a potent therapeutic approach to treat cancer diseases with the high efficacy. In order to optimize HER2 targeted therapies in breast cancer, we developed and characterized Trastuzumab-NPs conjugates.First, we synthesized hollow and porous silica nanoparticles (HPNPs) from a mold by sol-gel technique using tetraethylorthosilicate (TEOS) as a silicon precursor and as guides for the porous structure Tris Amine and CTAC, which are inexpensive and high commercial availability. HPNPs were analyzed by DLS and TEM obtaining spherical NPs of similar sizes (110±7.4 nm) with an internal hollow of 97±5.2 nm and pores of 2-5.4 nm with narrow distribution. In addition, Z potential was negative and the FTIR showed a characteristic band spectrum for silica without interferences. Then, the monoclonal antibody Trastuzumab (Tz), used in therapy for breast tumors HER2+, was adsorbed nonspecifically on the surface of the HPNPs, thereby obtaining a therapeutic nanotool. The binding was characterized by TEM and FTIR and remained stable for at least 30-40 days even in the lyophilized formulation. The maximum adsorption condition to avoid aggregates was 0.2 mg Tz/mg HPNPs. Tz-HPNPs were made in several mass ratios and we analized their cytotoxic effect on BT-474 (HER2+) and MDA-MB231 (HER2-) breast cancer cell lines for 72h. We found that Tz-HPNPs generated significant decrease on BT-474 viability, compared to treatment with tz alone (p